Brief: ABVC BioPharma Receives U.S. Patent for ADHD Treatment
21/11/2023 13:32
Nov 21 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA INC- RECEIVED U.S. PATENT FOR USE OF
PDC-1421,
TARGETING ATTENTION DEFICIT/HYPERACTIVITY DISORDER
Source text for Eikon: ID:nGNX1WTkXK
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner